Acima Private Wealth LLC Buys 200 Shares of Merck & Co., Inc. (NYSE:MRK)

Acima Private Wealth LLC raised its stake in Merck & Co., Inc. (NYSE:MRK) by 3.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,901 shares of the company’s stock after buying an additional 200 shares during the period. Acima Private Wealth LLC’s holdings in Merck & Co., Inc. were worth $537,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Atwater Malick LLC bought a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at about $57,000. 1 North Wealth Services LLC bought a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at about $58,000. American National Bank bought a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at about $67,000. Lenox Wealth Management Inc. boosted its position in shares of Merck & Co., Inc. by 23.3% during the 3rd quarter. Lenox Wealth Management Inc. now owns 793 shares of the company’s stock valued at $67,000 after purchasing an additional 150 shares in the last quarter. Finally, Balentine LLC boosted its position in shares of Merck & Co., Inc. by 58.4% during the 3rd quarter. Balentine LLC now owns 933 shares of the company’s stock valued at $79,000 after purchasing an additional 344 shares in the last quarter. Hedge funds and other institutional investors own 74.51% of the company’s stock.

Several equities research analysts recently commented on MRK shares. UBS Group upped their target price on Merck & Co., Inc. from $94.00 to $99.00 and gave the company a “buy” rating in a research report on Thursday. ValuEngine downgraded Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Tuesday, January 14th. Bank of America assumed coverage on Merck & Co., Inc. in a research note on Wednesday, October 16th. They set a “neutral” rating and a $90.00 price target on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $95.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, January 8th. Finally, Mizuho reaffirmed a “buy” rating and set a $100.00 price target on shares of Merck & Co., Inc. in a research note on Monday, January 6th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the stock. Merck & Co., Inc. currently has a consensus rating of “Buy” and a consensus target price of $96.38.

In other news, EVP Julie L. Gerberding sold 102,073 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $89.34, for a total value of $9,119,201.82. Following the completion of the sale, the executive vice president now directly owns 106,099 shares of the company’s stock, valued at $9,478,884.66. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.

MRK stock opened at $88.56 on Friday. The stock’s 50 day simple moving average is $90.26 and its 200 day simple moving average is $85.77. Merck & Co., Inc. has a fifty-two week low of $72.05 and a fifty-two week high of $92.64. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.98 and a current ratio of 1.26. The company has a market cap of $228.25 billion, a P/E ratio of 24.74, a price-to-earnings-growth ratio of 1.80 and a beta of 0.52.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 48.16% and a net margin of 20.26%. The business had revenue of $12.40 billion for the quarter, compared to the consensus estimate of $11.59 billion. During the same period in the prior year, the business earned $1.19 EPS. The firm’s revenue for the quarter was up 14.9% on a year-over-year basis. Equities analysts predict that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 8th. Stockholders of record on Monday, December 16th were paid a $0.61 dividend. The ex-dividend date was Friday, December 13th. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.55. This represents a $2.44 annualized dividend and a dividend yield of 2.76%. Merck & Co., Inc.’s dividend payout ratio is 56.22%.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: How is the discount rate different from the Federal Funds rate?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.